Advertisement
Advertisement
U.S. Markets open in 4 hrs 31 mins
Advertisement
Advertisement
Advertisement
Advertisement

Kala Pharmaceuticals, Inc. (KALA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.3323+0.0006 (+0.18%)
At close: 04:00PM EDT
0.3390 +0.01 (+2.02%)
Pre-Market: 04:53AM EDT
Advertisement

Kala Pharmaceuticals, Inc.

1167 Massachusetts Avenue
Arlington, MA 02476
United States
781 996 5252
https://www.kalarx.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees192

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark T. IwickiChairman & CEO919.89kN/A1966
Mr. Todd BazemorePres & COO671.58kN/A1970
Dr. Kim Brazzell Ph.D.Head of R&D and Chief Medical Officer645.19kN/A1953
Dr. Justin Hanes Ph.D.Founder & Chair of the Scientific Advisory BoardN/AN/AN/A
Ms. Mary Reumuth CPA, CPACFO & TreasurerN/AN/A1975
Ms. Jill S. SteierExec. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Eric L. TrachtenbergGen. Counsel, Chief Compliance Officer & Corp. Sec.N/AN/A1973
Ms. Michele LaRussaSr. VP of Regulatory Affairs & Quality AssuranceN/AN/A1970
Mr. Vincent KosewskiSr. VP of Manufacturing & Supply Chain ManagementN/AN/A1963
Mr. James PatnoeSr. VP of Market Access, Commercial Operations & PricingN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Kala Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 10. The pillar scores are Audit: 3; Board: 10; Shareholder Rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement